clevidipine has been researched along with oxybutynin in 3 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | clevidipine (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for clevidipine and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for clevidipine and oxybutynin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |